Switching from Semaglutide, a GLP-1 receptor agonist, to Zepbound (Tirzepatide) is possible, but should be done under the supervision of your healthcare provider
The study sera were assayed by the Roche Elecsys DCP and AFP kits, as well as the TASWako DCP, AFP and AFP-L3 kits, to calculate the GAAD and GALAD scores respectively using the algorithms provided by the manufacturers
This is usually a gradual, subtle shift rather than a dramatic change
Direct human data are absent, and no clinical trials have been conducted to date
Recent insights into mechanisms of beta-cell lipo- and glucolipotoxicity in Type 2 diabetes
So can keeping a food journal to help you spot old eating patterns as they crop up again